We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Test Predicts How Heart Attack Patients Will Respond to Mechanical Pumps

By HospiMedica International staff writers
Posted on 15 Feb 2024

Cardiogenic shock, a life-threatening condition often triggered by a severe heart attack, impairs the heart's ability to adequately pump blood. More...

To assist patients who experience cardiogenic shock, mechanical pumps known as percutaneous ventricular assist devices (VADs) are frequently utilized. These devices are inserted through the arteries and positioned across the aortic valve to aid the left ventricle – the heart chamber that pumps blood to most of the body's organs – in circulating blood. Typically, the VAD is removed after a week or so, once the heart regains its pumping capability. However, in some cases, VADs can disrupt the synchronous functioning of the heart's left and right ventricles, a complication observed in up to 43% of VAD recipients.

Researchers at MIT (Cambridge, MA, USA) conducted a study to understand the causes of this imbalance and identify predictive factors. The study aimed to understand the underlying reasons for this failure and to create a method for predicting its occurrence in patients. They also developed a test to help doctors anticipate this dysfunction in patients, thus aiding them in making informed decisions about using VADs. If doctors could foresee the need for right heart support, they might opt to implant an additional VAD for the right ventricle. Using an animal heart failure model, the researchers implanted a VAD in the left ventricle and observed various heart function metrics as the VAD's pumping speed was adjusted. They discovered that the key determinant in the right ventricle's response to VAD implantation was the pulmonary vascular system's ability to adapt to the VAD-induced changes in blood flow and volume. This adaptability was dependent upon the system's capacity to regulate resistance (slowing of steady blood flow) and compliance (accommodation of large blood volume pulses).

Furthermore, the researchers showed that assessing pulmonary vascular compliance and adaptability could predict patient response to left ventricular assistance. In a patient dataset, these measurements were consistent with the state of the right heart, confirming the adaptability to the VAD, thus validating the animal study results. To conduct this test, doctors would implant the VAD, then incrementally increase its speed while assessing the pulmonary vascular system's compliance. The researchers have established a metric for evaluating this compliance using the VAD and a commonly used pulmonary artery catheter. Going forward, the team aims to broaden these findings with more animal studies and continue collaborating with device manufacturers, to conduct clinical trials to determine the practicality and value of this test for medical professionals.

“We created this way to dynamically test the system while simultaneously maintaining support of the heart,” said Kimberly Lamberti, an MIT graduate student. “Once the device is initiated, this quick test could be run, which would inform clinicians of whether the patient might need right heart support.”

“The beauty of this study is that it uses pathophysiologic insight and advanced computational analyses to provide clinicians with straightforward guidelines as to how to deal with the exploding use of these valuable mechanical devices,” added Elazer Edelman, an MIT professor. “We use these devices increasingly in our sickest patients and now have greater strategies as to how to optimize their utility.”

Related Links:
MIT


Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Syringe Pump
SP50 Series
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image

Explainable AI Tool Improves Brain Disorder Screening from 4D fMRI

Functional magnetic resonance imaging (fMRI) captures changes in brain activity over time, but the resulting image sequences can be difficult to analyze. Screening for brain disorders requires assessing... Read more

Critical Care

view channel
Image: Liposomes have long been used for gradual drug delivery, with their composition controlling release speed, potency, duration, and potential toxicity. (Image Credit: iStock)

New Drug Delivery System Extends Release of Local Anesthetic for Weeks

Local anesthetics used for nerve blocks often provide pain relief for only a limited period, while perioperative pain can persist much longer. Extending the duration of a nerve block therefore requires... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.